To study vaginal development and sexual functioning in young women after childhood hemopoietic stem cell transplantation (HSCT) and radio/chemotherapy. Observational case-control study on 30 young sexually active women survived after HSCT and/or radio/chemotherapy for childhood malignancies or hematologic diseases and 48 controls matched for age. 
Introduction
In the last years, improvements in both management of hematopoietic stem cell transplantation (HSCT) and in chemo/radiotherapy have increased survival rates of childhood hematological diseases [1] . Adverse long-term consequences of treatment received during pediatric age and adolescence include both an overall life expectancy reduction and a worsening of the quality of life [1] . Most transplantation conditioning regimens include alkylating agents and/or body irradiation, which may cause gonadal dysfunction and premature ovarian failure in up to 90% of patients after HSCT [2] . Premature ovarian failure is a permanent loss of estrogenic production that leads to longterm complications, such as increased cardiovascular risk, bone loss, menopausal symptoms, vaginal atrophy, and sexual dysfunction [3] . Long-term sexual complications of pediatric HSCT include dyspareunia, vaginal dryness and scarring, and decreased libido, which can adversely affect quality of life [4] . Vaginal stenosis, scar tissue, and poor blood flow are reported in 26% of cases of chronic graft vs. host disease (GvHD) increasing sexual distress and pain [4, 5] . Vaginal maturation index (VMI) is an effective tool to evaluate the local effect of circulating estrogen levels and of hormonal replacement therapy (HRT). Reduction of VMI is a reliable measure of vaginal symptoms, like dryness, itching, dyspareunia, and pain [6] . VMI and vaginal atrophy have been used as measures of vaginal hormonal environment in mid-life women [7] and in breast cancer survivors [6] .
Data on long-term sexual functioning and on evaluation of vaginal atrophy, assessment of vaginal narrowing, and vaginal cytology in young women after treatment for childhood hematologic diseases are lacking. The purpose of the present study was to evaluate vaginal length, vaginal cytology, and sexual distress in young women who had received HSCT and/or radio/chemotherapy for childhood oncohematologic disease. We investigated also if HRT could improve these gynecological affections.
Materials/Subjects and methods
From September 2013 to May 2016 we enrolled a total of 30 nulliparous sexually active young women with a stable partner relationship who had received a childhood HSCT or chemotherapy/radiotherapy from 2003 to 2010. All subjects had been treated at the Pediatric Oncohematology Unit of IRCCS Policlinico San Matteo and were proposed to participate to the study during oncohematological and gynecological follow-up. Patients with findings of gynecological GvHD were excluded from the study. Fourty-eight nulliparous healthy controls were recruited among young subjects attending outpatient clinic for cytological screening and/or human papillomavirus vaccination program. None of them was taking hormonal contraceptives and they had a stable partner relationship and regular menstrual cycles. Out of 60 controls recruited, 48 (79.7%) subjects gave their consent and were included in the study.
Written informed consent was obtained by each enrolled patient. Each patient was included in an electronic database containing detailed information about the main disease, the treatment received and the kind of HRT, if administrated. Hormonal evaluation included plasma concentrations of follicle-stimulating hormone (FSH) (IU/L), luteinizing hormone (LH) (IU/L), and 17-β-estradiol (pg/mL) in cases with spontaneous cycles and controls in the early follicular phase (third day of cycle) using a commercial kit (Diagnostic Systems Laboratories, Inc. for 17-β-estradiol and Abbott Laboratories, Rome, Italy for FSH; Dade Behring, Milan, Italy for LH). At enrollment, all subjects received a structured interview about menstrual history and possible intake of HRT; they were given a sexual questionnaire and performed a gynecological exam for cytological sampling, evaluation of vaginal length and observation of presence/ absence of genital GvHD. To assess women sexual functioning, we used the Female Sexual Function Index (FSFI) [8] . This 19-item questionnaire (range 2-36) includes six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. A higher score in each domain indicates a better status. A FSFI total score of 26.55 seems to be the optimal cut score to discriminate women with and without sexual dysfunction, as defined by DSM-IV criteria [9, 10] . For measurement of sexual distress, we used the Female Sexual Distress Scale (FSDS). A score ≥ 11 discriminates between women with or without sexual distress [11, 12] . The VMI is a cytological indicator of the estrogenic stimulation of the vaginal epithelium and is calculated as ½ (percent intermediate cells) + percent superficial cells, being < 20 % in the case of an absent or low estrogenic effect, 20-60% in the case of a moderate estrogenic effect, and > 60% in the case of a high estrogenic effect [13] . VMI was evaluated on pap smear by a cytologist blinded to the status of the patients (case or control, type of treatment, etc.). The vaginal length was measured from the posterior vaginal fornix to the hymen ring by using a weighted speculum and not stretching the vagina; the distal end of a ring forceps was touched to the posterior vaginal fornix under direct visualization and then the speculum was removed. The point at which the forceps crossed the hymen ring was then Chemotherapy and radiotherapy (n = 9) 
Statistical analysis
Quantitative data and score questionnaires were not normally distributed (Shapiro test) and so they were described as median and inter quantile range (IQR 
Ethical approval
The study was approved by the Ethical Committee of our hospital (ref. no. 20130003837, 22 August 2013).
Results
The median age at enrollment was 20. Table 1 , non-malignant hematologic diseases (n = 8, 26.6%) included thalassemia and sickle cell anemia; malignant hematologic diseases (n = 20, 66.6%) included acute myeloid leukemia (n = 5), acute lymphoblastic leukemia (n = 4), and non-Hodgkin's lymphomas (n = 11); solid tumors (n = 2, 6.6%) included neuroblastoma (n = 1) and rhabdomyosarcoma (n = 1). Twenty-one subjects received HSCT, ten subjects with TBI and 11 with alkylating agents as conditioning treatment. Nine subjects received chemotherapy without HSCT, among these, seven received moreover chest radiotherapy for lymphomas and two received abdominal-pelvic radiotherapy for solid tumor. Overall, median age at main gonadotoxic treatment and time since treatment were 14 years (IQR = 10.5-16.3 years) and 8 years (IQR = 4-12 years), respectively. Twenty women (66.7%) were treated before and ten subjects (33.3%) after menarche. Twelve cases (40.0%) reported spontaneous ovarian activity with regular menstrual cycles. In these women, median follicular phase plasma concentrations of FSH, LH, and 17-βestradiol concentration were 5. menstrual cycles, among these, ten patients were currently treated with a HRT), a combination of estradiol 1.5 mg and nomegestrol 3.75 mg since a mean of 14 months (range 6-24 months), while eight patients did not receive any HRT because they were attending their first gynecological evaluation at our department. Among cases, spontaneously menstruating women, women in amenorrhea, and women with HRT did not differ for age at the enrollment (21. , respectively, adjusted p < 0.01. In particular, subjects treated by TBI, but not subjects conditioned by chemotherapy, had lower FSFI scores and shorter vaginal length when compared to those not receiving conditioning treatment (p = 0.004 and 0.05, respectively) (Table 3) . Furthermore, subjects who had received conditioning treatments had higher rates, even not significantly, of severe atrophy and moderate estrogenic stimulation than those treated by chemo-and radiotherapy (42.9% (9/21) vs. 11.1 % (1/9) and 28.6% (6/21) vs. 66.7% (6/9), p = 0.3) ( Table 4) . VMI was significantly correlated with FSFI and FSDS both in cases (Rho = 0.36, p = 0.05 and Rho = −0.607, p < 0.001) and in controls (Rho = 0.37, p = 0.011 and Rho = −0.408, p < 0.004). Disease category, main oncologic treatment after menarche, and time from the main treatment did not influence subsequent FSFI, FSDS scores, vaginal length, and VMI. Among cases, patients without both spontaneous cycles and replacement hormonal therapy (n = 8 patients) had lower overall FSFI score and higher FSDS score 18.6 (IQR = 13.2-22.9) and 24.0 (IQR 17-37.5), respectively, than patients with spontaneous cycles 27. (Table 5) .
Discussion
Our study, evaluating vaginal environment in young women survived to oncohematologic childhood cancer, focused on the severe impairment of gynecological functioning, with a lower vaginal length and maturation index, compared to healthy women. Several studies had already demonstrated the damages on gonadal function following conditioning chemotherapy and TBI, both because of direct effect on ovaries and on genital vascularization, leading to a reduced size of uterus and genital tract [14, 15] . Irradiation damage is irreversible and its effects are evident on the uterine musculature, with consequent fibrosis, which is not susceptible to improvement by HRT [15] . It's largely known that a lot of common chemotherapic agents induce vaginal dryness and loss of elasticity, firstly because of hypoestrogenism due to premature ovarian failure [3, 16] . On the other hand, radiation induces irreversible structural damage, affecting the basal layer of the mucosa, fibroblasts of the connective tissue in the submucosa, small mucosal vessels, and perivaginal tissues, inducing mucosal ischemia and circumferential fibrosis. For example, it has been reported that cervical carcinoma survivors presented vaginal length reduction after radiation therapy and, moreover, they experienced psychological, sexual, and social consequences [17] .
In comparison with other pelvic organs, the anatomy of vagina has been relatively poorly studied. In 2005 Sarpel et al. IQR interquartile range, FSFI Female Sexual Function Index (a score ≤ 26.55 discriminates between women with and without sexual dysfunction); FSDS Female Sexual Distress Scale (a score ≥ 11 discriminates between women with and without sexual distress), VMI vaginal maturation index (0 ≤ 20%, absent or low levels of estrogen; 1 = 20-60%, moderate levels of estrogen; 2 ≥ 60% high levels of estrogen) * p < 0.05 compared to women with no spontaneous menstrual cycle [18] established the normal ranges of vaginal length in premenstrual girls while studying the incidence of Complete Androgen Insensitivity Syndrome (CAIS). In 2006 Barnhart et al. [19] defined baseline, non-distended dimension of the vagina of women of reproductive age using a non-invasive imaging, MRI. Our results showed that cases had shorter vagina than controls, mainly if TBI had been used as conditioning therapy before HSCT. Furthermore, vaginal length was not improved by HRT, suggesting an irreversible damage.
To assess vaginal tropism, we performed Vaginal Maturation Index, a cytological parameter that indirectly reflects estrogen levels in vaginal site and correlates with vaginal atrophy and symptoms [3] . A decreased VMI is associated with vaginal dryness, dyspareunia, abnormal discharge, itch, and soreness [13] . VMI had been used in postmenopausal women [13] and in breast cancer survivors [6] to evaluate the effect of estrogenic treatment. We found lower VMI in cancer survivor compared to healthy women, mainly if patients had been treated with HSCT. Patients in amenorrhea, not taking any HRT, had lower VMI compared both to healthy control and to cases with spontaneous regular menstrual activity and to cases treated by HRT. This finding is correlated with a hypoestrogenic environment caused by ovarian damage induced by conditioning treatments. In this view a short vagina and a low VMI correlate with dyspareunia and a worse sexual function, according to our data on survivors. Sexual dysfunction is an important issue for survivors after HSCT [4] because of anatomical and functional damage after cancer treatment, but also because of psychological distress.
Female sexual response involves psychological and physical features, and sexual dysfunction. Baseline or pretransplantation depression, lack of desire, body image distortion, and anatomical damage are salient issues for patients after HSCT [20] . FSFI is the most used sexual function outcome measure, for research or clinical use, in healthy sexually active women [8] , but also in subjects treated for breast [10] , cervical [21, 22] , endometrial [22] , and ovarian cancer [23] . FSFI had been used as a measure of sexual function in cohort of subjects after HSCT, including adult women with 6.5-year-median time elapsed from cancer diagnosis [24] . Recently, Yoon et al. [25] used FSFI to evaluate sexual function in young adult childhood cancer survivors, finding a higher prevalence of sexual dysfunction in this population.
We used the FSDS to evaluate sexually related personal distress. FSDS score had been already used in breast and ovarian cancer survivors [10, 23] , reporting substantial sexual morbidity even years after treatment.
In 2017 Bevans et al. reported that data on long-term adult sexual function among subjects survived after childhood hematologic diseases are poor [1] . The rates of sexual dysfunction 5 years after HSCT among adult women rised up to 80% [26] .
After HSCT both males and females reported loss of libido; additional symptoms among women included pain during intercourse, vaginal dryness, and poor sexual satisfaction [4] . The few longitudinal studies of sexual health after HSCT consistently indicated that sexual dysfunction and sexual dissatisfaction are common [1, 27] .
Sexual functioning was also impaired in a Swedish study of 246 survivors using a semi-structured phone interview after a median of 16 years from diagnosis of childhood cancer [28] .
As expected, we found worse FSFI and FSDS in young female survivors compared to age-matched healthy controls. HSCT was associated with altered sexual functioning. Items concerning orgasm and sexual satisfaction were similar in cases and healthy women and this could be linked to the stable relationship in which all our patients were engaged. Our result could be explained by Rosen et al, that showed in 2000 that satisfaction item was overlapped with marital adjustment test [8] .
Most of the previous studies on quality of life and sexual function even in adults were carried out by telephone interview [20] , mail letters, or e-mails [29] with high rates of absent or incomplete responses. We provided the two self-administered questionnaires during scheduled followups. None of the subjects eligible for the study in our cohort refused to participate and all cases enrolled compiled entirely the proposed questionnaires.
A good estrogenic milieu plays a key role in sexual wellbeing. In fact, in our study the eight amenorrheic patients had lower FSFI and higher FSDS scores than controls and cases with spontaneous menstrual cycles or HRT. Conversely, spontaneous menstrual cycle was correlated with better both vaginal tropism and sexual function. These data underlined the need of HRT prescription to all women after gonadotoxic treatment to improve whole sexual function. HRT started 6-12 months after HSCT could have beneficial effects on sexuality in adult [14] .
The strength of our study was to investigate the whole sexual sphere evaluating vaginal length, vaginal tropism, and sexual function in oncohematologic diseases survivors of reproductive age. The inclusion of various types of childhood malignancies and non-malignant diseases did not permit specific inferences about single disease on sexual outcome and it is the main limitation of the study. We lack information about vaginal ultrasound Doppler vascularization; further studies are needed to correlate Doppler vaginal vascularization to tropism in this population.
Another further step would be to add to our data, during annual follow-up, information on how education, the risk of relapse and of infertility could have psychological influence on sexual function and distress.
In conclusion, the results of our study showed that conditioning treatments associated with childhood HSCT and/or radio/chemotherapy had severe adverse effect on vaginal development, sexual function, and sexual-related personal distress in young females. Ovarian and vaginal damage after irradiation and chemotherapy and subsequent low estrogen levels lead to a deterioration of vaginal cytology and to signs and symptoms typical of genitourinary syndrome of menopause.
The worst effects of previous treatment on sexual function were recorded on domains of desire, arousal, lubrication, and pain. Spontaneous menstrual activity and HRT seemed to be protective factors being associated with better sexual function and less sexual distress. Since local adverse vaginal effects of radio/chemotherapy associated with HSCT on subsequent sexual function seem heavy, both general and local estrogenic therapy should be promptly offered after the conclusion of oncologic main therapy.
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